Description: Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.
Home Page: www.hybio.com.cn
Hanyu Biological Park, No. 37
Shenzhen,
518057
China
Phone:
86 755 2658 8000
Officers
| Name | Title |
|---|---|
| Mr. Honghong Tu | Financial Director |
| Ms. Yu Pinxiang | Exec. VP & Director |
| Ms. Di Yang | VP, Sec. & Director |
| Mr. Zhaohui Zeng | VP |
| Ms. Min Zhang | VP |
| Mr. Jiancheng Yuan | Pres |
| Mr. Heng Quan | VP of Human Resource & Admin. Department |
| Mr. Yu Liu | VP of Marketing |
Exchange: SHE
Country: CN
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.7747 |
| Price-to-Sales TTM: | 29.2877 |
| IPO Date: | 2011-04-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 885 |